XIENCE PRIME Everolimus Eluting Coronary Stent Post Marketing Surveillance (PMS) in Japan
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Therapeutic Use
- Sponsors Abbott Vascular
- 07 Jun 2016 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 06 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 10 Dec 2012 New trial record